Emergent Biosolutions is pumping $50 million into upgrades at one of its Baltimore plants.
The biopharmaceutical firm said this month that it plans to complete the expansion of the fill/finish facility in Carroll-Camden over three years.
Gaithersburg–based Emergent Biosolutions makes vaccines and therapeutics, including an anthrax vaccine that is manufactured in Baltimore. The Carroll-Camden facility is one of multiple sites in the city, along with a manufacturing operation in Bayview that itself recently doubled in size.
The latest expansion will add to the company’s contract manufacturing operations, including a new fill line to fill vials, syringes and cartridges, as well as cold storage and office space. About 60 jobs are expected to be created.
“This $50 million investment further demonstrates our commitment to meeting and exceeding the expectations of our customers as well as to stimulating economic growth and creating jobs in Baltimore.” said BJ Hull, the company’s site head at Carroll-Camden.
The announcement came on the heels of another for the company with local implications. In May, Emergent and Baltimore-based Profectus Biosciences announced an agreement to collaborate on developing of a vaccine against the Nipah Virus. The $25 million effort is funded by the Coalition for Epidemic Preparedness Innovations. Under the deal, Profectus Biosciences will develop the treatment, and Emergent will provide technical assistance and receive a licensing option for the vaccine.-30-
Apache Software Foundation cofounder Jim Jagielski on the evolution of open source
Maryland to receive $5.7M in settlement over massive Equifax data breach
On the Market: Senior software engineer roles and more tech job openings in Baltimore
How law firm Nemphos Braue is guiding startups along the new business learning curve
Baltimore Corps wins $100K for platform connecting women and people of color to mission-driven tech jobs
Following Boston accelerator, Pinkaloo launches charitable giving pilot with Eastern Bank
This Annapolis fintech startup wants to make it easier for banks to work with cannabis businesses
Building a data acquisition system? Don’t make this mistake
Sign-up for daily news updates from Technical.ly Baltimore